A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)

A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)

Background: Venous thromboembolism is common in cancer patients and requires anticoagulation with low-molecular-weight heparin (LMWH). Current data recommend LMWH for anticoagulation as far as 6 months, yet guidelines recommend LMWH beyond 6 months in patients who have ongoing or active cancer. This...

Full description

Bibliographic Details
Main Authors: Simon I Noble, Annmarie Nelson, David Fitzmaurice, Marie-Jet Bekkers, Jessica Baillie, Stephanie Sivell, Joanna Canham, Joanna D Smith, Angela Casbard, Ander Cohen, David Cohen, Jessica Evans, Kate Fletcher, Miriam Johnson, Anthony Maraveyas, Hayley Prout, Kerenza Hood
Format: Article
Language:English
Published: NIHR Journals Library 2015-10-01
Series:Health Technology Assessment
Subjects:
venous thromboembolism
pulmonary embolus
deep-vein thrombosis
cancer-associated thrombosis
low-molecular-weight heparin
randomised controlled trial
mixed methods
palliative care
qualitative research
framework analysis
Online Access:https://doi.org/10.3310/hta19830

Similar Items

Similar Items